{"paper_id":"adda36df-2328-4f31-9a01-edf3e13215d3","body_text":"Print ISSN: 1021-335X\nOnline ISSN: 1791-2431\nInternational Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.\nInternational Journal of Oncology is an international journal devoted to oncology research and cancer treatment.\nCovers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.\nOncology Reports is an international journal devoted to fundamental and applied research in Oncology.\nExperimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.\nOncology Letters is an international journal devoted to Experimental and Clinical Oncology.\nExplores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.\nInternational journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.\nMultidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.\nOpen-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.\nPublishes open-access research on using epigenetics to advance understanding and treatment of human disease.\nAn International Open Access Journal Devoted to General Medicine.\nArticle\n- Authors:\n-\nPages: 457-463|Published online on: October 17, 2014https://doi.org/10.3892/or.2014.3550\n- Expand metrics +\nCancer cells can survive under hypoxia by metabolic reprogramming to achieve a high level of glycolysis, which contributes to the development of chemoresistance. Therefore, inhibition of glycolysis would be a novel strategy for overcoming hypoxia‑induced drug resistance. Baicalein, a flavonoid derived from the root of Scutellaria baicalensis, has been reported to exert strong antitumor activity toward various types of cancer. In the present study, we evaluated the effect of baicalein on hypoxia-induced 5-fluorouracil (5-FU) resistance in gastric cancer AGS cells and investigated the possible molecular mechanisms. We found that baicalein increased the sensitivity of AGS cells to 5-FU treatment under hypoxia. In addition, the hypoxia-enhanced glycolytic flux and expression of several critical glycolysis-associated enzymes (HK2, LDH-A and PDK1) in the AGS cells were suppressed by baicalein. Furthermore, baicalein inhibited hypoxia-induced Akt phosphorylation by promoting PTEN accumulation, thereby attenuating hypoxia-inducible factor-1α (HIF-1α) expression in AGS cells. These results together suggest that inhibition of glycolysis via regulation of the PTEN/Akt/HIF-1α signaling pathway may be one of the mechanisms whereby baicalein reverses 5-FU resistance in cancer cells under hypoxia.\nCopy and paste a formatted citation\nSpandidos Publications style\nChen F, Zhuang M, Zhong C, Peng J, Wang X, Li J, Chen Z and Huang Y: Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway. Oncol Rep 33: 457-463, 2015.\nAPA\nChen, F., Zhuang, M., Zhong, C., Peng, J., Wang, X., Li, J. ... Huang, Y. (2015). Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway. Oncology Reports, 33, 457-463. https://doi.org/10.3892/or.2014.3550\nMLA\nChen, F., Zhuang, M., Zhong, C., Peng, J., Wang, X., Li, J., Chen, Z., Huang, Y.\"Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway\". Oncology Reports 33.1 (2015): 457-463.\nChicago\nChen, F., Zhuang, M., Zhong, C., Peng, J., Wang, X., Li, J., Chen, Z., Huang, Y.\"Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway\". Oncology Reports 33, no. 1 (2015): 457-463. https://doi.org/10.3892/or.2014.3550","source_license":"CC0","license_restricted":false}